Kidney Disease Leader Travere Therapeutics Pulls Back To Key Level

Blockhead2024-11-19

Tuesday's IBD 50 Stocks To Watch pick is biotech stock Travere Therapeutics (TVTX), which is pulling back to a key support level. That makes the kidney disease leader one of the best ideas to watch ...

Source Link

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/2484212139?lang=en_US&edition=fundamental","thumbnail":"https://www.investors.com/wp-content/uploads/2024/09/Stock-TravereTherapeutics-01-shutt-640x360.jpg","is_english":true,"pubTime":"2024-11-19 23:48","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2484212139","market":"nz","top_or_hot":-1,"title":"Kidney Disease Leader Travere Therapeutics Pulls Back To Key Level","media":"Blockhead","content":"<div>\n<p>Tuesday's IBD 50 Stocks To Watch pick is biotech stock Travere Therapeutics (TVTX), which is pulling back to a key support level. That makes the kidney disease leader one of the best ideas to watch ...</p>\n\n<a href=\"https://www.investors.com/research/kidney-disease-travere-therapeutics-stock-tvtx/\">Source Link</a>\n\n</div>\n","source":"investor_business_daily_highlight","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Kidney Disease Leader Travere Therapeutics Pulls Back To Key Level</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nKidney Disease Leader Travere Therapeutics Pulls Back To Key Level\n</h2>\n\n<h4 class=\"meta\">\n\n\n2024-11-19 23:48 GMT+8&nbsp;&nbsp;&nbsp;<a href=https://www.investors.com/research/kidney-disease-travere-therapeutics-stock-tvtx/><strong>Blockhead</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>Tuesday's IBD 50 Stocks To Watch pick is biotech stock Travere Therapeutics (TVTX), which is pulling back to a key support level. That makes the kidney disease leader one of the best ideas to watch ...</p>\n\n<a href=\"https://www.investors.com/research/kidney-disease-travere-therapeutics-stock-tvtx/\">Source Link</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"LU0203201768.USD","symbol_name":"AB SICAV I - ALL MARKET INCOME PORTFOLIO \"AX\" (USD) INC","start_time":0,"source_url":"https://www.investors.com/research/kidney-disease-travere-therapeutics-stock-tvtx/","article_id":"2484212139","we_media_id":null,"thumbnails":["https://www.investors.com/wp-content/uploads/2024/09/Stock-TravereTherapeutics-01-shutt-640x360.jpg"],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2484212139","pubTimestamp":1732031298,"columns":[],"sourceInfo":{"source_id":"investor_business_daily_highlight","name":"Investor’s Business Daily"},"weMediaInfo":null,"summary":"Kidney disease leader Travere Therapeutics is pulling back to a key support level on the stock market today.","collect":0,"end_time":0,"defaultTopTitle":"investors.com","property":[],"viewcount":null,"language":"en","relate_stocks":{"LU0203201768.USD":"AB SICAV I - ALL MARKET INCOME PORTFOLIO \"AX\" (USD) INC","LU0354030438.USD":"富国美国大盘成长基金Cl A Acc","LU1674673691.USD":"HSBC GIF GLOBAL LOWER CARBON EQUITY \"AD\" (USD) INC","LU1815333072.USD":"THREADNEEDLE (LUX) GLOBAL FOCUS \"AUP\" (USD) INC","NVD":"GraniteShares 2x Short NVDA Daily ETF","SG9999001424.SGD":"United E-Commerce Fund SGD","IE00B1BXHZ80.USD":"Legg Mason ClearBridge - US Appreciation A Acc USD","SG9999015952.SGD":"LIONGLOBAL DISRUPTIVE INNOVATION \"I\" (SGD) ACC","LU0323591593.USD":"SCHRODER ISF QEP GLOBAL QUALITY \"A\" (USD) ACC","NVDX":"T-REX 2X LONG NVIDIA DAILY TARGET ETF","LU1280957306.USD":"THREADNEEDLE (LUX) US CONTRARIAN CORE EQUITIES \"AUP\" (USD) INC","LU2125154778.USD":"ALLSPRING GLOBAL EQUITY ENHANCED INCOME \"A\" (USD) INC","IE00B19Z8W00.USD":"FTGF CLEARBRIDGE US LARGE CAP GROWTH \"A\" INC","NVDA":"英伟达","LU0238689110.USD":"贝莱德环球动力股票基金","LU0957808578.USD":"THREADNEEDLE (LUX) GLOBAL TECHNOLOGY \"ZU\" (USD) ACC","LU0345768153.USD":"NINETY ONE GSF GLOBAL STRATEGIC MANAGED \"A\" (USD) ACC","NVDS":"Tradr 1.5X Short NVDA Daily ETF","TVTX":"Travere Therapeutics, Inc.","LU0289961442.SGD":"SUSTAINABLE GLOBAL THEMATIC PORTFOLIO \"AX\" (SGD) ACC","LU2125154935.USD":"ALLSPRING (LUX) WF GLOBAL EQUITY ENHANCED INCOME \"I\" (USD) INC","LU0345769631.USD":"NINETY ONE GSF GLOBAL EQUITY \"A\" (USD) INC","IE00BN29S564.USD":"JANUS HENDERSON BALANCED \"A3\" (USD) INC","LU0708995401.HKD":"FRANKLIN U.S. OPPORTUNITIES \"A\" (HKD) ACC","LU1366192091.USD":"ALLIANZ US EQUITY PLUS \"AM\" (USD) INC","NVDS.UK":"LS -1X NVIDIA","LU0256863902.USD":"ALLIANZ US EQUITY \"AT\" (USD) ACC","LU0316494557.USD":"FRANKLIN GLOBAL FUNDAMENTAL STRATEGIES \"A\" ACC","NVD2.UK":"2X NVIDIA ETP","LU2360107168.USD":"BGF NEXT GENERATION TECHNOLOGY \"A4\" (USD) INC","LU2491050071.SGD":"WELLINGTON SUSTAINABLE OUTCOMES \"A\" (SGDHDG) ACC","LU2360106780.USD":"BGF WORLD TECHNOLOGY \"A4\" (USD) INC","2NVD.UK":"2X NVIDIA ETP","ONON":"On Holding AG","IE0009356076.USD":"JANUS HENDERSON GLOBAL TECHNOLOGY AND INNOVATION \"A2\" (USD) ACC","IE00BJLML261.HKD":"HSBC GLOBAL EQUITY INDEX \"HCH\" (HKD) ACC","LENZ":"Therapeutics","NVD3.UK":"LS 3X NVIDIA","RYTM":"Rhythm Pharmaceuticals Inc.","LU2290526834.HKD":"BGF NEXT GENERATION TECHNOLOGY \"A2\" (HKDHDG) ACC","NVDY":"YIELDMAX NVDA OPTION INCOME STRATEGY ETF","LU0672654240.SGD":"FTIF - Franklin US Opportunities A Acc SGD-H1","3NVD.UK":"LS 3X NVIDIA","LU1242518857.USD":"FULLERTON LUX FUNDS - ASIA ABSOLUTE ALPHA \"I\" (USD) ACC","NVDD":"Direxion Daily NVDA Bear 1X Shares","LU2237957811.SGD":"NIKKO AM GLOBAL EQUITY \"F\" (SGD) ACC","NVDU":"Direxion Daily NVDA Bull 2X Shares","LU2592432038.USD":"WELLINGTON MULTI-ASSET HIGH INCOME \"A\" (USD) ACC","SNVD.UK":"LS -1X NVIDIA"},"translate_title":"肾脏疾病领导者Travere Therapeutics回落至关键水平","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"TVTX":1,"RYTM":1,"ONON":1,"LENZ":1,"NVDA":1,"NVD":0.6,"NVD2.UK":0.6,"NVD3.UK":0.6,"NVDD":0.6,"NVDS":0.6,"NVDS.UK":0.6,"NVDU":0.6,"NVDX":0.6,"NVDY":0.6,"SNVD.UK":0.6,"3NVD.UK":0.6,"2NVD.UK":0.6},"content_text":"Tuesday's IBD 50 Stocks To Watch pick is biotech stock Travere Therapeutics (TVTX), which is pulling back to a key support level. That makes the kidney disease leader one of the best ideas to watch right now.\nIn early October, Travere jumped to new highs after a group of experts suggested an alternative means of measuring the success of treatments for a kidney disease.\n\n\n\n↑\nX\n\n\n\n\nWall Street Stays Bullish On Nvidia Ahead Of Earnings. Can the AI Titan Outdo Itself Again?\n\n\nSee All Videos\n\n\n\n\nNOW PLAYING\nWall Street Stays Bullish On Nvidia Ahead Of Earnings. Can the AI Titan Outdo Itself Again?\n\n\n\n\nThe biotech company is working on a treatment for focal segmental glomerulosclerosis, or FSGS. In this condition, the kidney's filtering units become scarred or hardened. This leads to protein in the urine — called proteinuria — along with kidney failure and other complications.\nIn early September, Travere received full Food and Drug Administration approval for its kidney disease treatment, Filspari. Under the previous approval, doctors could use Filspari in the roughly 30,000 to 50,000 patients at risk for \"rapid progression\" of their disease.\nThe FDA removed that requirement, expanding the market to north of 70,000 patients in the U.S. with Immunoglobin A, or IgA. Also known as Berger's disease, it's a chronic condition that occurs when IgA protein builds up in the kidneys.\nIn the latest quarter, reported on Oct. 31, Travere Therapeutics narrowed its per-share loss to 46 cents compared with a year-ago loss of 87 cents a share. Sales climbed 70% to $62.9 million.\nFor the full year, Wall Street forecasts the company to lose $3.93 per share before cutting that loss to $1.16 per share in 2025, per IBD MarketSurge.\n\nThis Industry Group — And 4 IPOs — Polish 20 'Perfect' Gems\n\n\nKidney Disease Stock Pulls Back\nOn Nov. 11, Travere stock hit a 52-week high at 20.33. That's nearly 300% above its 52-week low at 5.12, which was set on April 25. Following that huge rally, shares are pulling back to their 10-week line. A strong rebound from that level would place the kidney disease leader in a new buy area.\nConversely, a sharp fall through that level would be a sell signal, an indication that investors are locking in substantial gains after the big move higher.\nBullishly, the stock's relative strength line hit a new high in recent weeks. That confirms the stock is beating the performance of the S&P 500.\nDespite strong price action in recent months, Travere Therapeutics stock maintains a modest 80 out of a best-possible 99 Composite Rating from Investor's Business Daily, according to IBD Stock Checkup. That's because the biotech stock doesn't have a long-term track record of earnings growth.\nFinally, while the stock market has retreated in recent sessions, IBD has maintained an exposure level of 80%-100%.\n\nNvidia, Apple And Tesla Highlight How To Handle This Market\n\nOther Stocks To Keep An Eye On\nThree recent IBD 50 Growth Stocks To Watch picks are among the best stocks to buy and watch.\n\n\n\nCompany\nSymbol\n Buy point\nType of base\n\n\n\n\nOn Holding\n (ONON)\n52.80\nFlat base\n\n\nNvidia\n (NVDA)\n140.76\nConsolidation\n\n\nRhythm Pharmaceuticals\n (RYTM)\n55.64\nConsolidation\n\n\n\nSource: IBD Data as of Nov. 19\nFollow Scott Lehtonen on X at @IBD_SLehtonen for more on the best stocks to buy and watch and the Dow Jones Industrial Average.\nYOU MAY ALSO LIKE:\nIBD's New Exposure Levels\nTop Growth Stocks To Buy And Watch\nLearn How To Time The Market With IBD's ETF Market Strategy\nFind The Best Long-Term Investments With IBD Long-Term Leaders\nSpot Buy Points And Sell Signals With MarketSurge Pattern Recognition","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"0","news_tag":"","news_rank":0,"symbols":[],"gpt_button":0},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"deviceId":"web-server-community-laohu8-v3","version":"4.30.2","shortVersion":"4.30.2","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2484212139"}